Cochrane · systematic review · CD001190
Donepezil for dementia due to Alzheimer's disease
Birks, JS, Harvey, RJ · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Dementia and Cognitive ImprovementAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
25
current version
GRADE rated
25
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 25 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Donepezil 10 mg/day compared with placebo for dementia due to Alzheimer's disease
Population: people with Alzheimer's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function (change from baseline at 26 weeks using ADAS‐Cog) Donepezil 10 mg/day vs placebo | no estimate extracted | 5 studies · 1130 participants | Moderate Downgraded: risk of bias |
Cognitive function (change from baseline at 26 weeks using MMSE) Donepezil 10 mg/day vs placebo | no estimate extracted | 7 studies · 1757 participants | Moderate Downgraded: risk of bias |
Activities of daily living (change from baseline at 26 weeks measured using the ADCS) Donepezil 10 mg/day vs placebo | no estimate extracted | 3 studies · 733 participants | Moderate Downgraded: risk of bias |
Clinician‐rated global impression tests (improved compared with baseline, measured using CIBIC‐plus at 24‐26 weeks) Donepezil 10 mg/day vs placebo | OR 1.92 [1.54, 2.39] | 6 studies · 1674 participants | Moderate Downgraded: risk of bias |
Behavioural symptoms (change from baseline at 26 weeks measured using the NPI) Donepezil 10 mg/day vs placebo | no estimate extracted | 4 studies · 1035 participants | Moderate Downgraded: risk of bias |
Acceptability of treatment (as measured by withdrawals from trial before end of treatment at 26 weeks) Donepezil 10 mg/day vs placebo | OR 1.25 [1.05, 1.5] | 12 studies · 2846 participants | Moderate Downgraded: risk of bias |
Incidence of adverse events (at least one adverse event by 26 weeks) Donepezil 10 mg/day vs placebo | OR 1.59 [1.31, 1.95] | 10 studies · 2500 participants | Moderate Downgraded: risk of bias |
Quality of life of participants (change from baseline at 26 weeks) Donepezil 10 mg/day vs placebo | no estimate extracted | 2 studies · 815 participants | Moderate Downgraded: risk of bias |
Donepezil 23 mg/day compared with donepezil 10 mg/day for dementia due to Alzheimer's disease
Population: people with Alzheimer's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function (change from baseline at 24 weeks using SIB) Donepezil 23 mg/day vs donepezil 10 mg/day | no estimate extracted | 2 studies · 1704 participants | Moderate Downgraded: risk of bias |
Cognitive function (change from baseline at 24 weeks using MMSE) Donepezil 23 mg/day vs donepezil 10 mg/day | no estimate extracted | 1 study · 1370 participants | Moderate Downgraded: risk of bias |
Activities of daily living (change from baseline at 24 weeks using the ADCS‐ADL‐sev) Donepezil 23 mg/day vs donepezil 10 mg/day | no estimate extracted | 1 study · 1396 participants | Moderate Downgraded: risk of bias |
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) Donepezil 23 mg/day vs donepezil 10 mg/day | OR 0.99 [0.78, 1.26] | 2 studies · 1704 participants | Moderate Downgraded: risk of bias |
Acceptability of treatment (as measured by withdrawals from trial before end of treatment at 24 weeks) Donepezil 23 mg/day vs donepezil 10 mg/day | OR 2.02 [1.59, 2.57] | 2 studies · 1818 participants | Moderate Downgraded: risk of bias |
Incidence of adverse events (at least one adverse event by 24 weeks) Donepezil 23 mg/day vs donepezil 10 mg/day | OR 1.65 [1.34, 2.03] | 2 studies · 1785 participants | Moderate Downgraded: risk of bias |
Donepezil 10 mg/day compared with donepezil 5 mg/day for dementia due to Alzheimer's disease
Population: people with Alzheimer's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function (change from baseline at 24 weeks using ADAS‐Cog) Donepezil 10 mg/day vs donepezil 5 mg/day | no estimate extracted | 2 studies · 818 participants | Moderate Downgraded: risk of bias |
Cognitive function (change from baseline at 24 weeks using MMSE) Donepezil 10 mg/day vs donepezil 5 mg/day | no estimate extracted | 1 study · 303 participants | Moderate Downgraded: risk of bias |
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) Donepezil 10 mg/day vs donepezil 5 mg/day | OR 1.26 [0.94, 1.67] | 3 studies · 981 participants | Moderate Downgraded: risk of bias |
Acceptability of treatment (as measured by withdrawals from trial before end of treatment at 24 weeks) Donepezil 10 mg/day vs donepezil 5 mg/day | OR 1.67 [1.24, 2.23] | 3 studies · 1052 participants | Moderate Downgraded: risk of bias |
Incidence of adverse events (at least one adverse event by 24 weeks) Donepezil 10 mg/day vs donepezil 5 mg/day | OR 1.56 [1.07, 2.28] | 2 studies · 741 participants | Moderate Downgraded: risk of bias |
Donepezil 10 mg/day compared with placebo for people with severe dementia due to Alzheimer's disease
Population: people with severe Alzheimer's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function (change from baseline at 26 weeks using MMSE) Donepezil 10 mg/day vs placebo | no estimate extracted | 4 studies · 1102 participants | Moderate Downgraded: risk of bias |
Cognitive function (change from baseline at 24 weeks using SIB) Donepezil 10 mg/day vs placebo | no estimate extracted | 5 studies · 1348 participants | Moderate Downgraded: risk of bias |
Clinician‐rated global impression tests (improved compared with baseline, measured using CIBIC‐Plus at 24 weeks) Donepezil 10 mg/day vs placebo | OR 1.78 [1.31, 2.43] | 3 studies · 755 participants | Moderate Downgraded: risk of bias |
Activities of daily living (change from baseline at 24 weeks using the ADCS‐ADL‐sev) Donepezil 10 mg/day vs placebo | no estimate extracted | 3 studies · 733 participants | Moderate Downgraded: risk of bias |
Acceptability of treatment (as measured by withdrawals from trial before end of treatment at 24 weeks) Donepezil 10 mg/day vs placebo | OR 1.32 [1.02, 1.71] | 5 studies · 1396 participants | Moderate Downgraded: risk of bias |
Incidence of adverse events (at least one adverse event by 24 weeks) Donepezil 10 mg/day vs placebo | OR 1.59 [1.23, 2.05] | 5 studies · 1396 participants | Moderate Downgraded: risk of bias |